|
1
|
Shtivelman E, Lifshitz B, Gale R and
Canaani E: Fused transcript of abl and bcr genes in chronic
myelogenous leukaemia. Nature. 315:550–554. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ben-Neriah Y, Daley G, Mes-Masson A, Witte
O and Baltimore D: The chronic myelogenous leukemia-specific P210
protein is the product of the BCR/ABL hybrid gene. Science.
233:212–214. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Quintas-Cardama A and Cortes J: Molecular
biology of bcr-abl1-positive chronic myeloid leukemia.
Blood. 113:1619–1630. 2009.
|
|
4
|
Baccarani M, Deininger MW, Rosti G, et al:
European LeukemiaNet recommendations for the management of chronic
myeloid leukemia: 2013. Blood. 122:872–884. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nash I: Chronic myeloid leukemia. N Engl J
Med. 341:7651999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Perrotti D, Jamieson C, Goldman J and
Skorski T: Chronic myeloid leukemia: mechanisms of blastic
transformation. J Clin Invest. 120:2254–2264. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen Y, Peng C, Li D and Li S: Molecular
and cellular bases of chronic myeloid leukemia. Protein Cell.
1:124–132. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rumpold H and Webersinke G: Molecular
pathogenesis of Philadelphia-positive chronic myeloid leukemia - is
it all BCR-ABL? Curr Cancer Drug Targets. 11:3–19. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Radich JP, Dai H, Mao M, et al: Gene
expression changes associated with progression and response in
chronic myeloid leukemia. Proc Natl Acad Sci USA. 103:2794–2799.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Feng G, Hui C and Pawson T: SH2-containing
phosphotyrosine phosphatase as a target of protein-tyrosine
kinases. Science. 259:1607–1611. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lorenz U: SHP-1 and SHP-2 in T cells: two
phosphatases functioning at many levels. Immunol Rev. 228:342–359.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li J, Xue L, Hao H, Han Y, Yang J and Luo
J: Rapamycin provides a therapeutic option through inhibition of
mTOR signaling in chronic myelogenous leukemia. Oncol Rep.
27:461–466. 2012.PubMed/NCBI
|
|
13
|
Dong Q, Siminovitch KA, Fialkow L,
Fukushima T and Downey GP: Negative regulation of myeloid cell
proliferation and function by the SH2 domain-containing tyrosine
phosphatase-1. J Immunol. 162:3220–3230. 1999.PubMed/NCBI
|
|
14
|
Tapley P, Shevde N, Schweitzer P, et al:
Increased G-CSF responsiveness of bone marrow cells from
hematopoietic cell phosphatase deficient viable motheaten mice. Exp
Hematol. 25:122–131. 1997.PubMed/NCBI
|
|
15
|
Oka T, Ouchida M, Koyama M, et al: Gene
silencing of the tyrosine phosphatase SHP1 gene by aberrant
methylation in leukemias/lymphomas. Cancer Res. 62:6390–6394.
2002.PubMed/NCBI
|
|
16
|
Chim CS, Fung TK, Cheung WC, Liang R and
Kwong YL: SOCS1 and SHP1 hypermethylation in multiple myeloma:
implications for epigenetic activation of the Jak/STAT pathway.
Blood. 103:4630–4635. 2004. View Article : Google Scholar
|
|
17
|
Zhang Q, Raghunath P, Vonderheid E, Odum N
and Wasik M: Lack of phosphotyrosine phosphatase SHP-1 expression
in malignant T-cell lymphoma cells results from methylation of the
SHP-1 promoter. Am J Pathol. 157:1137–1146. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Esposito N, Colavita I, Quintarelli C, et
al: SHP-1 expression accounts for resistance to imatinib treatment
in Philadelphia chromosome-positive cells derived from patients
with chronic myeloid leukemia. Blood. 118:3634–3644. 2011.
View Article : Google Scholar
|
|
19
|
Bruecher-Encke B, Griffin J, Neel B and
Lorenz U: Role of the tyrosine phosphatase SHP-1 in K562 cell
differentiation. Leukemia. 15:1424–1432. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kharbanda S, Bharti A, Pei D, et al: The
stress response to ionizing radiation involoves c-Abl-dependent
phosphorylation of SHPTP1. Proc Natl Acad Sci USA. 93:6898–6901.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hamilton A, Elrick L, Myssina S, et al:
BCR-ABL activity and its response to drugs can be determined in
CD34+ CML stem cells by CrkL phosphorylation status
using flow cytometry. Leukemia. 20:1035–1039. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lucas C, Harris R, Giannoudis A, Knight K,
Watmough S and Clark R: BCR-ABL1 tyrosine kinase activity at
diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of
clinical outcome in chronic myeloid leukaemia. Br J Haematol.
149:458–460. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
24
|
Khoury H, Kukreja M, Goldman J, et al:
Prognostic factors for outcomes in allogeneic transplantation for
CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant.
47:810–816. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chong Z and Maiese K: The Src homology 2
domain tyrosine phosphatases SHP-1 and SHP-2: diversified control
of cell growth, inflammation, and injury. Histol Histopathol.
22:1251–1267. 2007.PubMed/NCBI
|
|
26
|
Rawlings JS, Rosler KM and Harrison DA:
The JAK/STAT signaling pathway. J Cell Sci. 117:1281–1283. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Warsch W, Kollmann K, Eckelhart E, et al:
High STAT5 levels mediate imatinib resistance and indicate disease
progression in chronic myeloid leukemia. Blood. 117:3409–3420.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xie S, Wang Y, Liu J, et al: Involvement
of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
Oncogene. 20:6188–6195. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Samanta AK, Lin H, Sun T, Kantarjian H and
Arlinghaus RB: Janus kinase 2: a critical target in chronic
myelogenous leukemia. Cancer Res. 66:6468–6472. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Samanta A, Chakraborty S, Wang Y, et al:
Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1
pathway, causing apoptosis in drug-resistant cells from chronic
myelogenous leukemia patients. Oncogene. 28:1669–1681. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Samanta A, Perazzona B, Chakraborty S, et
al: Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid
leukemia. Leukemia. 25:463–472. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Luo J, Liu Z, Hao H, Wang F, Dong Z and
Ryuzo O: Mutation analysis of hematopoietic cell phosphatase gene
in acute leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 12:128–132.
2004.(In Chinese).
|
|
33
|
Amin H, Hoshino K, Yang H, Lin Q, Lai R
and Garcia-Manero G: Decreased expression level of SH2
domain-containing protein tyrosine phosphatase-1 (Shp1) is
associated with progression of chronic myeloid leukaemia. J Pathol.
212:402–410. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chim CS, Liang R, Leung MH and Kwong YL:
Aberrant gene methylation implicated in the progression of
monoclonal gammopathy of undetermined significance to multiple
myeloma. J Clin Pathol. 60:104–106. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang Q, Wang HY, Marzec M, Raghunath PN,
Nagasawa T and Wasik MA: STAT3- and DNA methyltransferase
1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor
suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci USA.
102:6948–6953. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Han Y, Amin HM, Franko B, Frantz C, Shi X
and Lai R: Loss of SHP1 enhances JAK3/STAT3 signaling and decreases
proteosome degradation of JAK3 and NPM-ALK in ALK+
anaplastic large-cell lymphoma. Blood. 108:2796–2803. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Neviani P, Santhanam R, Trotta R, et al:
The tumor suppressor PP2A is functionally inactivated in blast
crisis CML through the inhibitory activity of the BCR/ABL-regulated
SET protein. Cancer Cell. 8:355–368. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu C, Sun M, Liu L and Zhou G: The
function of the protein tyrosine phosphatase SHP-1 in cancer. Gene.
306:1–12. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Radich JP: The biology of CML blast
crisis. Hematology. 2007:384–391. 2007. View Article : Google Scholar
|
